Tandem Diabetes Care (TNDM) Corporate presentation summary

Market opportunity and company positioning

• Serves a large, underpenetrated global market with less than 40% of type 1 diabetes patients in the U.S. and less than 20% internationally using insulin pumps.

• Expanding reach to type 2 diabetes patients requiring intensive insulin therapy, where pump adoption is only about 5% in the U.S.

• Approximately 450,000 in-warranty customers across 25 countries as of December 2023.

• Headquartered in San Diego with around 2,400 employees worldwide.

Product portfolio and innovation

• Offers two main pump platforms: t:slim X2 and Tandem Mobi, both featuring Control-IQ technology and multiple CGM integrations.

• t:slim X2 is a touchscreen insulin pump, up to 38% smaller than competitors, with a 300-unit cartridge and mobile app bolus delivery.

• Tandem Mobi is the world’s smallest durable automated insulin delivery system, designed for discretion and smartphone control.

• Sigi platform and extended wear infusion sets are in development, aiming to expand adoption and customization.

• Tandem Source is a multi-sided diabetes management platform for patients, caregivers, clinicians, and admins, now available in the U.S. and Canada.

Technology and clinical validation

• Control-IQ technology predicts and helps prevent glucose highs and lows, with automated correction bolus and proven ease of use.

• Supported by three pivotal studies published in the New England Journal of Medicine.

• Demonstrated improvement in time-in-range for type 2 diabetes patients using GLP-1/SGLT-2 therapy in addition to insulin.